BBIO Stock Forecast & Price Target

BridgeBio Pharma is supported by a diversified late-stage pipeline that is increasingly de-risked by multiple positive clinical readouts, including sustained PROPEL 3 infigratinib data showing durable growth benefits plus improvements in sleep apnea, otitis media, and body composition, with no new safety signals over up to three years. Its first commercial asset, Attruby, is demonstrating strong traction in ATTR-CM, with Q2 U.S. sales of $222MM, up 23% sequentially and 211% year over year, while the broader TTR-CM market grew 19% quarter over quarter and 51% year over year and first-line share continued to expand, supporting confidence in durable launch economics. The investment case is further strengthened by a visible multi-catalyst path to value creation from three NDAs submitted and several regulatory milestones ahead, alongside a recent $1B preferred equity financing and $720MM of cash at the end of Q2, which together should help fund the rollout of additional programs while reducing near-term liquidity risk.

BridgeBio Pharma is viewed cautiously because, despite a broad late-stage pipeline, much of its valuation depends on a limited set of programs and assumptions around approval probabilities, while core assets still face meaningful clinical, regulatory, and commercialization risks. The company’s ~$1.9B debt load, including $450MM of senior secured debt due 2029, adds material financial strain and raises the stakes if cash flows from Attruby and other programs do not scale fast enough to service obligations, especially given covenant constraints and the potential need for additional funding or dilution. Although Attruby and other candidates like infigratinib and encaleret could drive upside, the stock’s fundamental risk/reward is weakened by the possibility of negative trial data, delayed filings, execution challenges in building U.S. commercial infrastructure, and broader drug-pricing and partnership risks that could impair long-term value creation.